Retrieval of Patient Information After Discontinuation

Inclusion Criteria

• •1. Signed, dated, and written informed consent obtained from the subject and/or the subject's legally acceptable representative (LAR, if applicable) in accordance with local regulations.
• •2. Signed, dated, and written informed consent, obtained from the subject's caregiver in accordance with local regulations.
• •3. Subject must have participated in the Study 301, 302, or 351 and have received at least 1 dose of study treatment (bapineuzumab or placebo).
• •4. Subject must have been off treatment for at least 12 months prior to Visit 1.
• •5. Subjects must have a primary caregiver for the duration of the study.
• •6. Subject's caregiver must have the ability to assess the subject and answer questions over the phone.